Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00892203 |
This study will assess the efficacy and safety of BGG492 used to treat migraine pain.
Condition | Intervention | Phase |
---|---|---|
Migraine |
Drug: BGG492 Drug: Sumatriptan Drug: Placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment |
Official Title: | A Multi-Centre, Randomized, Double-Blind, Parallel Group, Active and Placebo Controlled, Proof of Concept Study in Patients With Acute Migraine to Assess the Efficacy, Safety and Tolerability of Single Oral Doses of BGG492 |
Estimated Enrollment: | 75 |
Study Start Date: | April 2009 |
Estimated Primary Completion Date: | August 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Active: Experimental | Drug: BGG492 |
Comparator: Active Comparator | Drug: Sumatriptan |
Placebo: Placebo Comparator | Drug: Placebo |
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Germany | |
Novartis Investigative Site | Recruiting |
Essen, Germany | |
Contact: Novartis +41-61-324-1111 | |
Novartis Investigator Site | Recruiting |
Munich, Germany | |
Contact: Novartis +41-61-324-1111 | |
Novartis Investigator Site | Recruiting |
Hamburg, Germany | |
Contact: Novartis +41-61-324-1111 | |
Novartis Investigative Site | Recruiting |
Kiel, Germany | |
Contact: Novartis +41-61-324-1111 |
Study Director: | Novartis Pharmaceuticals | Novartis Investigator Site |
Responsible Party: | Novartis Pharmaceuticals ( External Affairs ) |
Study ID Numbers: | CBGG492A2204, 2008-005392-10 |
Study First Received: | May 1, 2009 |
Last Updated: | May 1, 2009 |
ClinicalTrials.gov Identifier: | NCT00892203 History of Changes |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices; Spain: Spanish Agency of Medicines |
Migraine Headache |
Serotonin Agonists Sumatriptan Neurotransmitter Agents Migraine Disorders Headache Vasoconstrictor Agents |
Central Nervous System Diseases Headache Disorders, Primary Cardiovascular Agents Brain Diseases Serotonin Headache Disorders |
Serotonin Agonists Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Nervous System Diseases Central Nervous System Diseases Headache Disorders, Primary Cardiovascular Agents |
Brain Diseases Pharmacologic Actions Headache Disorders Sumatriptan Serotonin Agents Migraine Disorders Therapeutic Uses Vasoconstrictor Agents |